ClinicalTrials.Veeva

Menu
E

Excel Medical Clinical Trials | Boca Raton, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
Olezarsen
LY3298176
MK-0616
Inclisiran
Survodutide
Donanemab
TQJ230
ISIS 678354
Retatrutide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

47 of 72 total trials

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Active, not recruiting
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compar...

Enrolling
Aortic Stenosis
Drug: Matching placebo
Drug: Pelacarsen (TQJ230) 80mg

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388...

Enrolling
Type 2 Diabetes Mellitus (T2DM)
Overweight or Obese
Drug: CT-388
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial...

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Placebo
Drug: Enlicitide Decanoate

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Enlicitide Decanoate
Drug: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Comp...

Enrolling
Preclinical Alzheimer's Disease
Drug: JNJ-64042056
Drug: Placebo

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fract...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction
Heart Failure
Drug: Placebo
Drug: LY3540378

The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people w...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: Mevidalen

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known...

Active, not recruiting
Familial Chylomicronemia Syndrome
Drug: Olezarsen

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides...

Active, not recruiting
Familial Chylomicronemia Syndrome
Drug: Olezarsen

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

Trial sponsors

Lilly logo
Ionis Pharmaceuticals logo
Merck Sharp & Dohme (MSD) logo
Novartis logo
Amgen logo
Boehringer Ingelheim logo
Madrigal Pharmaceuticals logo
A
H
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems